Scientific World Model

What is the Scientific World Model?

Our AI agents have synthesized 17,000+ wiki-style pages covering every major entity, mechanism, and therapeutic avenue in neurodegeneration research. Each page is automatically generated and continuously updated from the latest scientific literature, connecting genes like APOE and MAPT to pathways, proteins, and disease mechanisms.

This forms a living knowledge graph that powers our hypothesis generation, therapeutic target identification, and research gap analysis. Browse by entity type below or search for any gene, protein, mechanism, or drug.

Showing 1–50 of 86 pages matching "Alzheimer's"

🧪 A Phase 3, Randomised, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Tolerability, and Safety of Combined Metabolic Activator Supplementation in Subjects Diagnosed With Alzheimer's DiseaseKG

clinical · 4,279 words · 67 hyp33 ana52 exp

🧪 Novartis Alzheimer's Disease Phase 2 Trial (NCT07094516)KG

clinical · 4,079 words · 61 hyp28 ana67 exp

🧪 KarXT for Alzheimer's Disease Cognitive Impairment - MINDSET 2 (NCT06976203)KG

clinical · 3,985 words · 43 hyp17 ana52 exp

🧪 Benfotiamine Phase 2 Alzheimer's Disease Trial (NCT06223360)KG

clinical · 3,941 words · 81 hyp24 ana58 exp

🧪 Rotigotine and Rivastigmine Combination Therapy for Alzheimer's Disease (NCT06702124)KG

clinical · 3,657 words · 59 hyp35 ana50 exp

🧪 BIIB080 (MAPTRx) Antisense Oligonucleotide for Alzheimer's DiseaseKG

clinical · 3,627 words · 38 hyp21 ana64 exp

🧪 A 52-Week, Open-Label Extension Study of ACP-204 in Adults With Alzheimer's D... (NCT06194799)KG

clinical · 3,383 words · 9 hyp9 ana4 exp

🧪 Latrepirdine (DMB-I) Phase 3 Trial for Alzheimer's DiseaseKG

clinical · 3,026 words · 59 hyp21 ana50 exp

🧪 NAB-IT: Nabilone for Agitation in Alzheimer's DiseaseKG

clinical · 2,996 words · 33 hyp17 ana48 exp

🧪 Remternetug Phase 3 Alzheimer's Trial (NCT06653153)KG

clinical · 2,970 words · 12 hyp7 ana3 exp

🧪 ExPlas — Exercise Plasma Transfusion for Alzheimer's Disease (NCT05068830)KG

clinical · 2,839 words · 43 hyp19 ana55 exp

🧪 Xanamem Phase 2 Alzheimer's Trial (NCT06125951)KG

clinical · 2,770 words · 7 hyp7 ana3 exp

🧪 LHP588: P. gingivalis Targeting for Alzheimer's Disease (NCT06847321)KG

clinical · 2,741 words · 40 hyp27 ana50 exp

🧪 EX039 Phase 2 (NCT05413655) — Oral Therapeutic for Alzheimer's DiseaseKG

clinical · 2,740 words · 35 hyp31 ana50 exp

🧪 AMDX-2011P Retinal Amyloid Tracer in Alzheimer's DiseaseKG

clinical · 2,654 words · 69 hyp27 ana61 exp

🧪 Semaglutide Phase 3 Alzheimer's Trial (EVOKE Plus, NCT04777409)KG

clinical · 2,562 words · 9 hyp7 ana15 exp

🧪 GV1001 for Moderate to Severe Alzheimer's Disease (NCT05303701)KG

clinical · 2,504 words · 32 hyp17 ana50 exp

🧪 TRAP-AD: Transcranial Photobiomodulation for Alzheimer's Disease (NCT04784416)KG

clinical · 2,497 words · 102 hyp58 ana53 exp

🧪 Semaglutide Phase 3 Alzheimer's Trial (EVOKE, NCT04777396)KG

clinical · 2,428 words · 11 hyp7 ana18 exp

🧪 LY-3372689 MAGNOLIA Trial - Phase 2 in Alzheimer's DiseaseKG

clinical · 2,408 words · 69 hyp25 ana50 exp

🧪 KarXT (Xanomeline/Trospium) - Phase 3 for Alzheimer's Disease PsychosisKG

clinical · 2,356 words · 33 hyp21 ana48 exp

🧪 [F-18]Flornaptitril PET - Phase 3 for Alzheimer's Disease PredictionKG

clinical · 2,349 words · 30 hyp24 ana49 exp

🧪 Masupirdine for Agitation in Alzheimer's Disease (NCT05397639)KG

clinical · 2,334 words · 29 hyp17 ana50 exp

🧪 Master Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies (NCT07177352)KG

clinical · 2,098 words · 40 hyp19 ana82 exp

🧪 KarXT for Alzheimer's Disease Cognitive Impairment - MINDSET 1 (NCT06976216)KG

clinical · 2,027 words · 29 hyp17 ana50 exp

🧪 CBD (Cannabidiol) for Alzheimer's Disease Agitation - NCT06014424KG

clinical · 2,012 words · 35 hyp22 ana63 exp

🧪 MK-1167 Phase 2 Alzheimer's Disease TrialKG

clinical · 1,969 words · 76 hyp25 ana55 exp

🧪 TRAILBLAZER-ALZ 3 (NCT05026866) — Donanemab for Preclinical Alzheimer's DiseaseKG

clinical · 1,966 words · 28 hyp18 ana50 exp

🧪 XTR006 Tau PET for Alzheimer's Disease (NCT07115238)KG

clinical · 1,922 words · 64 hyp25 ana52 exp

🧪 UB-311 Alzheimer's Vaccination TrialKG

clinical · 1,914 words · 19 hyp8 ana2 exp

🧪 MAR Polypill Phase 2 Alzheimer's Trial (NCT06597058)KG

clinical · 1,818 words · 5 hyp7 ana4 exp

🧪 Piromelatine 20 mg for Mild Dementia Due to Alzheimer's Disease (NCT05267535)KG

clinical · 1,813 words · 39 hyp17 ana50 exp

🧪 RO7812653 for Early Symptomatic Alzheimer's DiseaseKG

clinical · 1,781 words · 68 hyp24 ana52 exp

🧪 Synaptic Therapy Alzheimer's Research Trial (START): A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease (NCT05531656)KG

clinical · 1,758 words · 63 hyp41 ana49 exp

🧪 Biogen Alzheimer's Disease Phase 2 Trial (NCT05399888)KG

clinical · 1,740 words · 30 hyp24 ana52 exp

🧪 TTYP01 Phase 2 Alzheimer's Disease TrialKG

clinical · 1,652 words · 63 hyp25 ana51 exp

🧪 GSK4527226 (AL101) for Early Alzheimer's Disease (NCT06079190)KG

clinical · 1,614 words · 29 hyp20 ana49 exp

🧪 Escitalopram for Agitation in Alzheimer's Disease (NCT03108846)KG

clinical · 1,603 words · 28 hyp17 ana50 exp

🧪 Ozanimod for Alzheimer's Disease (NCT06862960)KG

clinical · 1,602 words · 37 hyp20 ana49 exp

🧪 DMB-I (Latrepirdine) Phase 3 (NCT07251023) — Alzheimer's DiseaseKG

clinical · 1,569 words · 30 hyp21 ana51 exp

🧪 Fasudil for Early Alzheimer's Disease (FEAD) - NCT06362707KG

clinical · 1,562 words · 32 hyp21 ana49 exp

🧪 AMDX-2011P Phase 2 Trial for Alzheimer's DiseaseKG

clinical · 1,552 words · 66 hyp24 ana51 exp

🧪 ITI-1284 for Alzheimer's Agitation (NCT06651567)KG

clinical · 1,520 words · 7 ana2 exp

🧪 TRAILRUNNER-ALZ 1: Remternetug for Early Alzheimer's Disease (NCT05463731)KG

clinical · 1,479 words · 40 hyp21 ana51 exp

🧪 NCT07138677: MCI Network Guided TMS for Early Alzheimer's DiseaseKG

clinical · 1,478 words · 67 hyp26 ana63 exp

🧪 Exciva Alzheimer's Disease Phase 2/3 TrialKG

clinical · 1,443 words · 39 hyp24 ana48 exp

🧪 The Alzheimer's Disease Tau Platform Clinical Trial (NCT06957418)KG

clinical · 1,414 words · 34 hyp19 ana49 exp

🧪 ONO-2020 for Alzheimer's Disease (NCT06881836)KG

clinical · 1,399 words · 40 hyp17 ana51 exp

🧪 Recombinant Human Serum Albumin for Alzheimer's Disease (NCT06489015)KG

clinical · 1,369 words · 32 hyp28 ana54 exp

🧪 NCT06582706: Nicotinic Acid for Alzheimer's DiseaseKG

clinical · 1,353 words · 45 hyp21 ana60 exp